Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Boehringer Ingelheim Soars with Jardiance Growth as US Kidney Disease Approval Looms
Source – Boehringer Ingelheim Boehringer Ingelheim is gearing up for the launch of Jardiance, a diabetes and heart failure drug, ...
First-ever JUVĆDERM Day is announced by Allergan Aesthetics
Source – Abbvie That sounds like an exciting announcement! Allergan Aesthetics, now an AbbVie company, is celebrating the first-ever JUVĆDERM ...
Even after buying Prometheus for $10.8 billion, Merck is still looking for M&A opportunities
Earlier this year, Merck’s acquisition of Prometheus Biosciences for $10.8 billion provided the New Jersey company with a much-needed diversification ...
TheracosBio’s Bold Move: New CEO Takes Charge After FDA Approval and Price Showdown with Diabetes Drug Brenzavvy
TheracosBio, after securing its first-ever FDA approval for the SGLT2 diabetes drug Brenzavvy, has undergone a CEO change, with Brian ...
TG Therapeutics Partners with Neuraxpharm to Launch Game-Changing Multiple Sclerosis Antibody Briumvi Worldwide
After gaining approval for Briumvi in the US eight months ago, TG Therapeutics is now set to introduce its multiple ...
Blockbuster Cancer Immunotherapy Showdown Ends: Bristol Myers Squibb and AstraZeneca Settle Patents Clash
Bristol Myers Squibb (BMS) and AstraZeneca have quickly resolved patent infringement lawsuits related to their cancer immunotherapies. The companies reached ...
The VOYAGER Trial Illustrates the Potential of ctDNA in GIST
ctDNA analysis is a valuable tool in monitoring disease progression and tailoring treatments for patients with gastrointestinal stromal tumor (GIST), ...
Beginning of TNG260 and Pembrolizumab Study in Advanced Solid Tumors
The first patient has received a dose of TNG260 in combination with pembrolizumab (Keytruda) as part of a Phase I/II ...
FDA rejects Citius’ resurrected IL-2 lymphoma treatment
Source – Citius PharmaceuticalsĀ The FDA has declined Citius Pharmaceuticals’ request to market Lymphir, an updated version of a lymphoma ...
AstraZeneca Expects Higher China Sales, Denies Spinoff Report
AstraZenecaās CEO Pascal Soriot has denied a report that the company is considering spinning off its China business, which is ...
Biogen Buys Reata and Skyclarys for $7.3B, Cuts Jobs
During a quarterly earnings call, Biogen CEO Chris Viehbacher unexpectedly mentioned that the company had around $7.3 billion in cash. ...
Teva Aims for Growth by 2027 After $4.25B Opioid Settlement
Teva Pharmaceutical is shifting its focus back to its core businesses in generics and biosimilars, seeing promising opportunities in both ...
Roche Halts Development of Tenecteplase for Stroke
Roche announced today that it has discontinued the development of its thrombolytic drug tenecteplase for acute ischemic stroke due to ...
Enhertu increases survival in solid tumors with HER2+
AstraZeneca and Daiichi Sankyo have received a boost in their efforts to gain approval for Enhertu as a therapy for ...
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
Lundbeck and Otsuka Collaborate to Raise Awareness of Alzheimer’s Agitation Treatment
Lundbeck and Otsuka have intensified their efforts to address a niche area in Alzheimer’s disease treatment. Following their FDA approval ...
Vabysmo, Roche’s Top Eye Medicine, Crosses Blockbuster Threshold Ahead of Competitors
According to Roche’s pharma chief, Teresa Graham, their eye drug Vabysmo is currently experiencing significant momentum. Since its FDA approval ...
Gilead’s Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer Receives European Commission Approval
Source – Gilead Gilead Sciences, has received approval from the European Commission (EC) for the use of Trodelvy (sacituzumab govitecan) ...
Teva Seeks Appeal in Kickbacks Case Amid $10 Billion Trial Risk
Teva has been grappling with opioid litigation for several years, culminating in a multibillion-dollar settlement last year. However, the company ...
Qunol, a rapidly expanding US brand in the healthy aging market, will be acquired by Sanofi
Source – Sanofi Paris, July 28, 2023. Sanofi announces its strategic move to acquire Qunol, a renowned and leading brand ...
Bristol Myers lowers the company’s 2023 revenue forecast for Revlimid by $1 billion
Bristol Myers Squibb (BMS) had a promising long-term outlook after securing FDA approvals for three drugs with peak sales potential ...
Sharon Barr is appointed executive vice president of biopharmaceuticals R&D by AstraZeneca
Source – AstraZeneca AstraZeneca has made a significant leadership announcement, appointing Sharon Barr as the new Executive Vice President for ...
AbbVie Raises Profit Expectations Despite Q2 Decrease in Humira and Imbruvica Sales
AbbVie executives express satisfaction with the introduction of Humira biosimilars in the US, despite facing significant revenue declines for both ...
Merck’s V116 Vaccine Shows Positive Results in Phase III Trials
Source – Merck Merck, known as MSD outside of the United States and Canada, has announced highly encouraging initial results ...
Teva’s CEO Francis Recruits Angus Grant, Former BeiGene Business Development Head
Teva Pharmaceutical Industries Ltd., the worldās largest maker of generic drugs, has announced the appointment of a new executive to ...
As Vyvanse generics loom, Takeda exaggerates the progress of the dengue vaccine launch
As generics of the popular ADHD medication Vyvanse loom on the horizon, Takeda is looking to rely on newer launches ...
Skyrizi Beats Placebo in Psoriasis Phase 4 Study
Source – Abbvie On July 26, 2023 AbbVie announced the publication of results from the Phase IVĀ IMMpulse study in ...
Sanofi Reports ‘Solid’ Q2 Performance with 3 Ongoing Launches and Dupixent Nearing ā¬10B Milestone
Sanofi, a leading pharmaceutical company, is navigating the challenges posed by the entry of generic versions of its drug Aubagio ...
Pfizer reveals executive leadership to advance its oncology R&D strategy
Source – Pfizer Pfizer has unveiled significant executive leadership changes aimed at advancing its commitment to research and development of ...
Humanigen Struggles Amidst Failed Reverse Merger, Faces Looming Bankruptcy
Three years ago, Humanigen was on a promising trajectory with a COVID-19 therapy in advanced testing and shares valued at ...
